Shanti Ramachandran

Dr. Shanti Ramachandran

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2023 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
JCJohn Coutsouvelis
John Coutsouvelis
CKCarl M. Kirkpatrick
Carl M. Kirkpatrick
MDMichael Dooley
Michael Dooley
Andrew SpencerAndrew Spencer
Andrew Spencer
GKGlen Kennedy
Glen Kennedy
NHNada Hamad
Nada Hamad
Sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) is an established complication in patients undergoing allogeneic hemopoietic stem cell transplantation (HSCT). Defibrotide is an effective and safe pharmacologic option for treating diagnosed SOS/VOD. By exploring data provided to the Australasian Bone Marrow Transplant Recipient Registry (ABMTRR) by centers in Australia and New Zealand, this study aimed to describe the incidence of SOS/VOD and patterns of defibrotide use from 2016 to 2020. Patients who underwent allogeneic hemopoietic stem cell transplantation between 2016 and 2020 were identified from the ABMTRR. Data were extracted for a total of 3346 patients, 2692 from adult centers and 654 from pediatric centers, with a median follow-up of 21.5 months and 33.3 months, respectively. Descriptive statistics were used to describe the patient population, including the incidence of SOS/VOD and defibrotide use. Comparisons were made between patients without SOS/VOD and those with SOS/VOD, divided into defibrotide and no defibrotide cohorts. Associations with overall survival (OS) and day 100 survival with such variables as sex, age, disease at transplantation, stem cell source, conditioning agents, SOS/VOD diagnosis, and use of defibrotide, were determined. The reported incidence of SOS/VOD was 4.1% in adult centers and 11.5% in pediatric centers. Defibrotide was administered to 74.8% of adult patients and 97.3% of pediatric patients with SOS/VOD. Significant variability in the use, dosage, and duration of defibrotide was seen across the adult centers. The day 100 survival rate and median OS for patients managed with defibrotide was 51.8% and 103 days, respectively, for adult patients and 90.4% and not reached, respectively, for pediatric patients. In adults, older age at transplantation, an HLA-matched nonsibling relative donor, and a diagnosis of SOS/VOD treated with defibrotide were associated with reduced OS. In pediatric patients, the patient and transplantation characteristics associated with reduced OS were a diagnosis of SOS/VOD and a ≥2 HLA-mismatched related donor. A collaborative approach across Australasia to diagnosing and managing SOS/VOD, particularly with respect to consistent defibrotide use, is recommended.

20 October 2019 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
EFEliska Furlong
Eliska Furlong
JJJesper Jensen
Jesper Jensen
MWMark Woodard
Mark Woodard
KGKatherine Griffiths
Katherine Griffiths
GKGeoff Knight
Geoff Knight
SRShanti Ramachandran
Shanti Ramachandran

16 August 2021 in Australasian Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
AFAaron J Frederiks
Aaron J Frederiks
DSDominic V Spagnolo
Dominic V Spagnolo
SRShanti Ramachandran
Shanti Ramachandran
RBRoland Brand
Roland Brand

6 April 2025 in Cancers
Verified
Journal Article
Open access
PDF file
CPClare Parker
Clare Parker
CSClarissa Schilstra
Clarissa Schilstra
KMKaren Mccleary
Karen Mccleary
MMMichelle Martin
Michelle Martin
TTToby Trahair
Toby Trahair
JFJoanna E. Fardell
Joanna E. Fardell
Background/Objectives: Parents of children with acute lymphoblastic leukaemia (ALL) experience emotional distress throughout their child’s treatment course. This study describes the psychological experience of Australian and New Zealand parents of children diagnosed with ALL. Methods: This prospective, longitudinal study assessed distress, anxiety, depression, anger and the need for help in parents of children with newly diagnosed ALL across eight sites between October 2018 and November 2022. Psychological symptoms were quantified using the Emotion Thermometer (ET) tool and Patient-Reported Outcome Measurement Information System (PROMIS) questionnaires. Participants were recruited within ninety days of chemotherapy commencement, with surveys distributed bimonthly thereafter. Results: One hundred and seventeen participants completed 327 survey responses spanning 0 to 62 months post-diagnosis. Parental distress peaked within the first 6 months and 40% of parents reported clinically significant symptoms across four or more domains as measured by our questionnaires. Anxiety was the most consistently elevated symptom, with over 50% of responses above the clinical cut-off. Depression and the need for help also peaked closer to diagnosis and declined over time. In contrast, anger remained stable, with 27% reporting clinically significant scores across all time points. Increased time since diagnosis was significantly associated with reductions in distress, anxiety and depression scores. Conclusions: Australian and New Zealand parents experience high levels of psychological distress within the first six months following their child’s diagnosis of ALL. A notable minority continue to report elevated distress levels over time, identifying a need for improved psychological support for family wellbeing throughout the ALL treatment trajectory.

5 May 2014 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
SRShanti Ramachandran
Shanti Ramachandran
AAAngela Alessandri
Angela Alessandri
JPJames Price
James Price
SBShanti Balasubramaniam
Shanti Balasubramaniam

20 November 2026 in Transplantation and Cellular Therapy
Verified
Journal Article
Closed access
MHMiles Horton
Miles Horton
HWHannah Walker
Hannah Walker
TCTheresa Cole
Theresa Cole
DYDaniel Yeoh
Daniel Yeoh
SSShivanthan Shanthikumar
Shivanthan Shanthikumar
GHGabrielle M. Haeusler
Gabrielle M. Haeusler